Enanta Pharmaceuticals (FRA:9EP) Short-Term Capital Lease Obligation : €2.03 Mil (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals Short-Term Capital Lease Obligation?

Enanta Pharmaceuticals's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was €2.03 Mil.

Enanta Pharmaceuticals's quarterly Short-Term Capital Lease Obligation declined from Sep. 2024 (€1.37 Mil) to Dec. 2024 (€0.96 Mil) but then increased from Dec. 2024 (€0.96 Mil) to Mar. 2025 (€2.03 Mil).

Enanta Pharmaceuticals's annual Short-Term Capital Lease Obligation increased from Sep. 2022 (€2.92 Mil) to Sep. 2023 (€4.94 Mil) but then declined from Sep. 2023 (€4.94 Mil) to Sep. 2024 (€1.37 Mil).

Enanta Pharmaceuticals Short-Term Capital Lease Obligation Historical Data

The historical data trend for Enanta Pharmaceuticals's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals Short-Term Capital Lease Obligation Chart

Enanta Pharmaceuticals Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

3.62

3.57

2.92

4.94

1.37

Enanta Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															3.30	2.26	1.37	0.96	2.03

Enanta Pharmaceuticals Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Enanta Pharmaceuticals Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Enanta Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (FRA:9EP) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ENTA:USA

Address

4 Kingsbury Avenue, Watertown, MA, USA, 02472

Website

https://www.enanta.com

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals Headlines

No Headlines